PDS Biotechnology Corp (PDSB): Nasdaq/NYSE listing notice — PDS Biotechnology receives Nasdaq bid price deficiency notice; 180 days to cure

PDS Biotechnology Corp

Stock closed below $1.00 for 30 consecutive business days, triggering Nasdaq Listing Rule 5550(a)(2) deficiency.
Company has 180 calendar days, until August 24, 2026, to regain compliance by closing at $1.00+ for 10 consecutive days.
If not compliant by deadline, company may seek a second 180-day period if it meets other listing standards.
Potential remedies include a reverse stock split; delisting could occur if compliance is not achieved.
Common stock continues trading on Nasdaq under symbol PDSB with no immediate impact.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

PDS Biotechnology Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

February 25, 2026, PDS Biotechnology Corporation (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s comm

View on SEC.gov

Browse all listing & compliance notices →

PDS Biotechnology Corp filing history →

Source: SEC EDGAR

accession 0001140361-26-007478

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.